Global Targeted DNA Sequencing Market
Description
MARKET SCOPE:
The global Targeted DNA Sequencing market is projected to grow significantly, registering a CAGR of 12.1% during the forecast period (2024 – 2032).
Targeted DNA sequencing is an approach to high-throughput sequencing that selectively captures and sequences specific segments of the genome rather than the entire genomic content. This methodology enables researchers to concentrate on particular genomic regions of interest, providing a cost-effective and efficient means to analyze targeted genes or specific genomic areas. Researchers have the flexibility to choose particular genomic regions, such as coding sequences, exons, or regions linked to specific diseases, for targeted sequencing, resulting in a more focused analysis compared to whole-genome sequencing. The process of targeted DNA sequencing involves the creation of a sequencing library designed to selectively capture the identified genomic regions. This is commonly achieved through the utilization of DNA probes or baits that selectively bind to the specified regions of interest. Subsequently, the prepared library undergoes a capture or enrichment step, isolating the targeted genomic regions. This critical step ensures that the sequenced data predominantly originates from the selected regions, enhancing the precision and relevance of the analysis.
MARKET OVERVIEW:
Driver: Technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery is driving the market growth.
The progress in DNA sequencing technologies has significantly propelled market growth. According to the NHGRI, advancements and enhancements in technology have rapidly evolved and reduced costs since the completion of the Human Genome Project. As a result, some laboratories are now capable of sequencing over 100 trillion bases annually. Notable DNA sequencing equipment such as Biomek 4000, Hudson Robotics SOLO, Formulatrix Mantis, Hamilton Microlab NIMBUS, Hamilton Genomic STARlet, Eppendorf epMotion 5075t, Beckman Coulter Biomek i5, Tecan NGS, PerkinElmer Sciclone G3 NGS and NGSx Workstation, Hamilton NGS STAR, Beckman Coulter Biomek i7, and Agilent Bravo NGS have played a crucial role in refining the DNA sequencing process.
Opportunities: Continued research and development activities as well as growing usage of novel procedures are expected to pave the way for market growth in the upcoming years.
The market growth is anticipated to receive a significant boost due to the increasing adoption of advanced DNA sequencing techniques. Emerging procedures such as high-throughput sequencing, ion-torrent sequencing, pyrosequencing, single-molecule real-time sequencing, sequencing by synthesis, sequencing by ligation, combinatorial probe anchor synthesis, GenapSys sequencing, Sanger sequencing, and Nanopore sequencing leverage various technologies including electrical tunnelling, hybridization, mass spectrometry, in vitro virus mRNA display, microscopy, and microfluidics. These methods find applications in DNA sequencing, DNA synthesis, RNA sequencing, gene sequencing, as well as sample preparation for DNA and RNA polymerase. The incorporation of these diverse and innovative techniques is expected to create ample growth opportunities for the market in the future.
COVID IMPACT:
The global market for targeted DNA sequencing, akin to various industries, has felt the repercussions of the COVID-19 pandemic. The outbreak resulted in disruptions within supply chains, obstacles in research and development initiatives, and a realignment of healthcare priorities. As the healthcare sector confronted the overwhelming demands of addressing the pandemic, resources were redirected from routine diagnostics and research pursuits, impacting the progression of targeted DNA sequencing projects. Furthermore, lockdowns, travel restrictions, and adherence to social distancing measures disrupted the regular operations of laboratories and research facilities, causing delays in sample processing and data generation. Despite these challenges, the pandemic highlighted the significance of genomics in comprehending infectious diseases, reigniting interest in targeted DNA sequencing for scrutinizing the genetic aspects of the virus and its effects on host populations. Anticipated recovery is on the horizon as research activities resume, and the emphasis on personalized medicine and genomic research gains momentum in the post-pandemic landscape. The ongoing advancements in the targeted DNA sequencing market continue to shape the industry's strategies in response to the evolving challenges posed by the global health crisis.
SEGMENTATION ANALYSIS:
The sequencing segment is anticipated to grow significantly during the forecast period.
As sequencing costs decrease and throughput capability improves, sequencing is gaining momentum across various applications, with an increasing number of companies integrating Next-Generation Sequencing (NGS) into clinical practices. This trend is anticipated to persist in the clinical setting in the coming years, propelled by market opportunities in areas such as liquid biopsy and average-risk Non-Invasive Prenatal Testing (NIPT). In January 2021, Illumina announced several oncology partnerships with Merck, Myriad Genetics, Kura Oncology, and Bristol Myers Squibb, aiming to expand the utilization and reach of its TruSight Oncology pan-cancer assay.
The hospital segment is anticipated to grow significantly during the forecast period.
The segment encompassing hospitals and clinics is expected to experience substantial growth, driven by a growing number of patients seeking personalized care. The increased adoption of Next-Generation Sequencing (NGS) services in hospitals and clinics, aimed at assessing disease progression rates and optimizing tailored treatment plans for chronic conditions, has been a key contributor to the segment's expansion. Leading market players like Illumina, offering clinical services such as CLIA-certified tests for predisposition screening, molecular diagnostic tests for cystic fibrosis, and postnatal cytogenetics, are poised to contribute significantly to revenue growth in the foreseeable future.
REGIONAL ANALYSIS:
The Asia Pacific region is set to witness significant growth during the forecast period.
The Asia Pacific market is expected to experience accelerated growth in the foreseeable future, attributed to the rising expenditure on research and development, coupled with the availability of advanced technology for drug discovery and development. Notably, Japan and China have witnessed noteworthy advancements in integrating Next-Generation Sequencing (NGS) technologies, aligning with the clinical development frameworks of emerging economies like Australia and India, thereby presenting substantial growth prospects. In August 2022, Illumina unveiled plans to expand its regional presence by establishing a new manufacturing unit in China, aimed at supplying gene sequencing products. This strategic move reflects the company's commitment to tapping into the growing opportunities within the dynamic Asia Pacific market.
COMPETITIVE ANALYSIS
The global Targeted DNA Sequencing market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Illumina Inc.
Azenta US, Inc. (GENEWIZ)
BGI Group (MGI Tech Co., Ltd.)
CD Genomics
Daicel Corporation (Daicel Arbor Biosciences)
(Integrated DNA Technologies, Inc.)
Hoffmann-La Roche Ltd
LGC Limited (LGC Biosearch Technologies)
PerkinElmer Inc.
Psomagen
QIAGEN N.V.
Takara Bio Inc.
Tecan Trading AG
Thermo Fisher Scientific Inc.
Twist Bioscience
SCOPE OF THE REPORT
By Technology
It provides a technological development map over time to understand the industry’s growth rate and indicates how the Targeted DNA Sequencing market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Targeted DNA Sequencing submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
The global Targeted DNA Sequencing market is projected to grow significantly, registering a CAGR of 12.1% during the forecast period (2024 – 2032).
Targeted DNA sequencing is an approach to high-throughput sequencing that selectively captures and sequences specific segments of the genome rather than the entire genomic content. This methodology enables researchers to concentrate on particular genomic regions of interest, providing a cost-effective and efficient means to analyze targeted genes or specific genomic areas. Researchers have the flexibility to choose particular genomic regions, such as coding sequences, exons, or regions linked to specific diseases, for targeted sequencing, resulting in a more focused analysis compared to whole-genome sequencing. The process of targeted DNA sequencing involves the creation of a sequencing library designed to selectively capture the identified genomic regions. This is commonly achieved through the utilization of DNA probes or baits that selectively bind to the specified regions of interest. Subsequently, the prepared library undergoes a capture or enrichment step, isolating the targeted genomic regions. This critical step ensures that the sequenced data predominantly originates from the selected regions, enhancing the precision and relevance of the analysis.
MARKET OVERVIEW:
Driver: Technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery is driving the market growth.
The progress in DNA sequencing technologies has significantly propelled market growth. According to the NHGRI, advancements and enhancements in technology have rapidly evolved and reduced costs since the completion of the Human Genome Project. As a result, some laboratories are now capable of sequencing over 100 trillion bases annually. Notable DNA sequencing equipment such as Biomek 4000, Hudson Robotics SOLO, Formulatrix Mantis, Hamilton Microlab NIMBUS, Hamilton Genomic STARlet, Eppendorf epMotion 5075t, Beckman Coulter Biomek i5, Tecan NGS, PerkinElmer Sciclone G3 NGS and NGSx Workstation, Hamilton NGS STAR, Beckman Coulter Biomek i7, and Agilent Bravo NGS have played a crucial role in refining the DNA sequencing process.
Opportunities: Continued research and development activities as well as growing usage of novel procedures are expected to pave the way for market growth in the upcoming years.
The market growth is anticipated to receive a significant boost due to the increasing adoption of advanced DNA sequencing techniques. Emerging procedures such as high-throughput sequencing, ion-torrent sequencing, pyrosequencing, single-molecule real-time sequencing, sequencing by synthesis, sequencing by ligation, combinatorial probe anchor synthesis, GenapSys sequencing, Sanger sequencing, and Nanopore sequencing leverage various technologies including electrical tunnelling, hybridization, mass spectrometry, in vitro virus mRNA display, microscopy, and microfluidics. These methods find applications in DNA sequencing, DNA synthesis, RNA sequencing, gene sequencing, as well as sample preparation for DNA and RNA polymerase. The incorporation of these diverse and innovative techniques is expected to create ample growth opportunities for the market in the future.
COVID IMPACT:
The global market for targeted DNA sequencing, akin to various industries, has felt the repercussions of the COVID-19 pandemic. The outbreak resulted in disruptions within supply chains, obstacles in research and development initiatives, and a realignment of healthcare priorities. As the healthcare sector confronted the overwhelming demands of addressing the pandemic, resources were redirected from routine diagnostics and research pursuits, impacting the progression of targeted DNA sequencing projects. Furthermore, lockdowns, travel restrictions, and adherence to social distancing measures disrupted the regular operations of laboratories and research facilities, causing delays in sample processing and data generation. Despite these challenges, the pandemic highlighted the significance of genomics in comprehending infectious diseases, reigniting interest in targeted DNA sequencing for scrutinizing the genetic aspects of the virus and its effects on host populations. Anticipated recovery is on the horizon as research activities resume, and the emphasis on personalized medicine and genomic research gains momentum in the post-pandemic landscape. The ongoing advancements in the targeted DNA sequencing market continue to shape the industry's strategies in response to the evolving challenges posed by the global health crisis.
SEGMENTATION ANALYSIS:
The sequencing segment is anticipated to grow significantly during the forecast period.
As sequencing costs decrease and throughput capability improves, sequencing is gaining momentum across various applications, with an increasing number of companies integrating Next-Generation Sequencing (NGS) into clinical practices. This trend is anticipated to persist in the clinical setting in the coming years, propelled by market opportunities in areas such as liquid biopsy and average-risk Non-Invasive Prenatal Testing (NIPT). In January 2021, Illumina announced several oncology partnerships with Merck, Myriad Genetics, Kura Oncology, and Bristol Myers Squibb, aiming to expand the utilization and reach of its TruSight Oncology pan-cancer assay.
The hospital segment is anticipated to grow significantly during the forecast period.
The segment encompassing hospitals and clinics is expected to experience substantial growth, driven by a growing number of patients seeking personalized care. The increased adoption of Next-Generation Sequencing (NGS) services in hospitals and clinics, aimed at assessing disease progression rates and optimizing tailored treatment plans for chronic conditions, has been a key contributor to the segment's expansion. Leading market players like Illumina, offering clinical services such as CLIA-certified tests for predisposition screening, molecular diagnostic tests for cystic fibrosis, and postnatal cytogenetics, are poised to contribute significantly to revenue growth in the foreseeable future.
REGIONAL ANALYSIS:
The Asia Pacific region is set to witness significant growth during the forecast period.
The Asia Pacific market is expected to experience accelerated growth in the foreseeable future, attributed to the rising expenditure on research and development, coupled with the availability of advanced technology for drug discovery and development. Notably, Japan and China have witnessed noteworthy advancements in integrating Next-Generation Sequencing (NGS) technologies, aligning with the clinical development frameworks of emerging economies like Australia and India, thereby presenting substantial growth prospects. In August 2022, Illumina unveiled plans to expand its regional presence by establishing a new manufacturing unit in China, aimed at supplying gene sequencing products. This strategic move reflects the company's commitment to tapping into the growing opportunities within the dynamic Asia Pacific market.
COMPETITIVE ANALYSIS
The global Targeted DNA Sequencing market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Illumina Inc.
- In January 2022, Illumina Inc. unveiled the NovaSeq X Series, consisting of NovaSeq X and NovaSeq X Plus, which represents a new line of production-scale next-generation sequencers. These advanced sequencers are designed to enhance the speed, potency, and sustainability of sequencing processes.
Azenta US, Inc. (GENEWIZ)
BGI Group (MGI Tech Co., Ltd.)
CD Genomics
Daicel Corporation (Daicel Arbor Biosciences)
(Integrated DNA Technologies, Inc.)
Hoffmann-La Roche Ltd
LGC Limited (LGC Biosearch Technologies)
PerkinElmer Inc.
Psomagen
QIAGEN N.V.
Takara Bio Inc.
Tecan Trading AG
Thermo Fisher Scientific Inc.
Twist Bioscience
SCOPE OF THE REPORT
By Technology
- Sequencing
- Re-sequencing
- Electrophoresis-based resequencing
- NGS
- Array-based resequencing
- DNA-based targeted sequencing
- RNA-based targeted sequencing
- Clinical application
- Plant and animal sciences
- Drug development
- Others
- Hospitals & clinics
- Academic research
- Others
- North America (the United States & Canada)
- Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
- Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
- Rest of the World (the Middle East & Africa, and Latin America)
It provides a technological development map over time to understand the industry’s growth rate and indicates how the Targeted DNA Sequencing market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Targeted DNA Sequencing submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
Table of Contents
174 Pages
- 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Regional Analysis
- 1.3. Segment Analysis
- 2. Overview And Scope
- 2.1. Market Vision
- 2.1.1. Market Definition
- 2.2. Market Segmentation
- 3. Global Targeted Dna Sequencing Market Overview By Region: 2019 Vs 2024 Vs 2032
- 3.1. Global Targeted Dna Sequencing Market Size By Regions (2019-2023) (Usd Million)
- 3.1.1. North America Targeted Dna Sequencing Market Size By Country (2019-2023) (Usd Million)
- 3.1.2. Europe Targeted Dna Sequencing Market Size By Country (2019-2023) (Usd Million)
- 3.1.3. Asia Pacific America Targeted Dna Sequencing Market Size By Country (2019-2023) (Usd Million)
- 3.1.4. Rest Of The World Targeted Dna Sequencing Market Size By Country (2019-2023) (Usd Million)
- 3.2. Global Targeted Dna Sequencing Market Size By Regions (2024-2032) (Usd Million)
- 3.2.1. North America Targeted Dna Sequencing Market Size By Country (2024-2032) (Usd Million)
- 3.2.2. Europe Targeted Dna Sequencing Market Size By Country (2024-2032) (Usd Million)
- 3.2.3. Asia Pacific Targeted Dna Sequencing Market Size By Country (2024-2032) (Usd Million)
- 3.2.4. Rest Of The World Targeted Dna Sequencing Market Size By Country (2024-2032) (Usd Million)
- 4. Global Targeted Dna Sequencing Market Dynamics
- 4.1. Market Overview
- 4.1.1. Market Drivers
- 4.1.2. Market Restraints/ Challenges Analysis
- 4.1.3. Market Opportunities
- 4.2. Pestle Analysis
- 4.3. Porter’s Five Forces Model
- 4.3.1. Bargaining Power Of Suppliers
- 4.3.2. Bargaining Power Of Buyers
- 4.3.3. The Threat Of New Entrants
- 4.3.4. Threat Of Substitutes
- 4.3.5. Intensity Of Rivalry
- 4.4. Value Chain Analysis/Supply Chain Analysis
- 4.5. Covid-19 Impact Analysis On Global Targeted Dna Sequencing Market
- ** In – Depth Qualitative Analysis Will Be Provided In The Final Report Subject To Market
- 5. Global Targeted Dna Sequencing Market, By Technology
- 5.1. Overview
- 5.2. Global Targeted Dna Sequencing Market Size By Technology
- 5.3. Key Findings For Targeted Dna Sequencing Market - By Technology
- 5.3.1. Sequencing
- 5.3.2. Re-sequencing
- 5.3.2.1. Electrophoresis-based Resequencing
- 5.3.2.2. Ngs
- 5.3.2.3. Array-based Resequencing
- 6. Global Targeted Dna Sequencing Market, By Type
- 6.1. Overview
- 6.2. Key Findings For Targeted Dna Sequencing Market - By Type
- 6.2.1. Dna-based Targeted Sequencing
- 6.2.2. Rna-based Targeted Sequencing
- 7. Global Targeted Dna Sequencing Market, By Application
- 7.1. Overview
- 7.2. Key Findings For Targeted Dna Sequencing Market - By Application
- 7.2.1. Clinical Application
- 7.2.2. Plant And Animal Sciences
- 7.2.3. Drug Development
- 7.2.4. Others
- 8. Global Targeted Dna Sequencing Market, By End Users
- 8.1. Overview
- 8.2. Key Findings For Targeted Dna Sequencing Market - By End Users
- 8.2.1. Hospitals & Clinics
- 8.2.2. Academic Research
- 8.2.3. Others
- 9. Global Targeted Dna Sequencing Market, By Region
- 9.1. Overview
- 9.2. Key Findings For Targeted Dna Sequencing Market- By Region
- 9.3. Global Targeted Dna Sequencing Market, By Technology
- 9.4. Global Targeted Dna Sequencing Market, By Type
- 9.5. Global Targeted Dna Sequencing Market, By Application
- 9.6. Global Targeted Dna Sequencing Market, By End Users
- 10. Global Targeted Dna Sequencing Market- North America
- 10.1. Overview
- 10.2. North America Targeted Dna Sequencing Market Size (2019 - 2032) (Usd Million)
- 10.3. North America Targeted Dna Sequencing Market, By Technology
- 10.4. North America Targeted Dna Sequencing Market, By Type
- 10.5. North America Targeted Dna Sequencing Market, By Application
- 10.6. North America Targeted Dna Sequencing Market, By End Users
- 10.7. North America Targeted Dna Sequencing Market Size By Countries
- 10.7.1. United States
- 10.7.2. Canada
- 11. Global Targeted Dna Sequencing Market- Europe
- 11.1. Overview
- 11.2. Europe Targeted Dna Sequencing Market Size (2019 - 2032) (Usd Million)
- 11.3. Europe Targeted Dna Sequencing Market, By Technology
- 11.4. Europe Targeted Dna Sequencing Market, By Type
- 11.5. Europe Targeted Dna Sequencing Market, By Application
- 11.6. Europe Targeted Dna Sequencing Market, By End Users
- 11.7. Europe Targeted Dna Sequencing Market Size By Countries
- 11.7.1. Germany
- 11.7.2. Uk
- 11.7.3. France
- 11.7.4. Spain
- 11.7.5. Italy
- 11.7.6. Rest Of Europe
- 12. Global Targeted Dna Sequencing Market - Asia Pacific
- 12.1. Overview
- 12.2. Asia Pacific Targeted Dna Sequencing Market Size (2019 - 2032) (Usd Million)
- 12.3. Asia Pacific Targeted Dna Sequencing Market, By Technology
- 12.4. Asia Pacific Targeted Dna Sequencing Market, By Type
- 12.5. Asia Pacific Targeted Dna Sequencing Market, By Application
- 12.6. Asia Pacific Targeted Dna Sequencing Market, By End Users
- 12.7. Asia Pacific Targeted Dna Sequencing Market Size By Countries
- 12.7.1. China
- 12.7.2. Japan
- 12.7.3. India
- 12.7.4. Rest Of Asia Pacific
- 13. Global Targeted Dna Sequencing Market- Rest Of World
- 13.1. Overview
- 13.2. Rest Of World Targeted Dna Sequencing Market Size (2019 - 2032) (Usd Million)
- 13.3. Rest Of World Targeted Dna Sequencing Market, By Technology
- 13.4. Rest Of World Targeted Dna Sequencing Market, By Type
- 13.5. Rest Of World Targeted Dna Sequencing Market, By Application
- 13.6. Rest Of World Targeted Dna Sequencing Market, By End Users
- 13.7. Rest Of World Targeted Dna Sequencing Market Size By Regions
- 13.7.1. Middle East & Africa
- 13.7.2. Latin America
- 14. Global Targeted Dna Sequencing Market- Competitive Landscape
- 14.1. Key Strategies Adopted By The Leading Players
- 14.2. Recent Developments
- 14.2.1. Investments & Expansions
- 14.2.2. New End-user Launches
- 14.2.3. Mergers & Acquisitions
- 14.2.4. Agreements, Joint Ventures, And Partnerships
- 15. Global Targeted Dna Sequencing Market- Company Profiles
- 15.1. Illumina, Inc.
- 15.1.1. Company Overview
- 15.1.2. Financial Overview
- 15.1.3. Product Offered
- 15.1.4. Key Developments
- 15.2. Azenta Us, Inc. (Genewiz)
- 15.3. Bgi Group (Mgi Tech Co., Ltd.)
- 15.4. Cd Genomics
- 15.5. Daicel Corporation (Daicel Arbor Biosciences)
- 15.6. (Integrated Dna Technologies, Inc.)
- 15.7. Hoffmann-la Roche Ltd
- 15.8. Lgc Limited (Lgc Biosearch Technologies)
- 15.9. Perkinelmer Inc.
- 15.10. Psomagen
- 15.11. Qiagen N.V.
- 15.12. Takara Bio Inc.
- 15.13. Tecan Trading Ag
- 15.14. Thermo Fisher Scientific Inc.
- 15.15. Twist Bioscience
- 16. Our Research Methodology
- 16.1. Data Triangulation
- 16.2. Data Sources
- 16.2.1. Secondary Sources
- 16.2.2. Primary Sources
- 16.3. Assumptions/ Limitations For The Study
- 16.4. Research & Forecasting Methodology
- 17. Appendix
- 17.1. Disclaimer
- 17.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
